Articles

Find an Article

Filter articles

Applied Filters

Showing 271 to 280 of 334 results

Patent decisions: a clash of the courts

US27-11-2014Felicia Boyd

The US Supreme Court has now heard arguments in the appeal of Teva v Sandoz from the US Court of Appeals for the Federal Circuit. This could fundamentally change how patent decisions are reviewed by the Federal Circuit and the deference given to district court rulings, says Felicia Boyd of Barnes & Thornburg.

Apotex appeal: cold feet in Canada

Canada27-11-2014Gunars Gaikis

The Supreme Court of Canada was expected to bring the Canadian law on utility more into line with other jurisdictions, but those hopes have now received a setback, as Gunars Gaikis of Smart & Biggar/Fetherstonhaugh reports.

Pursuing agribusiness infringement actions in Brazil

Brazil04-11-2014Gabriel Di Blasi

Protecting rights related to desirable plant species is a delicate process, says Gabriel Di Blasi.

A changing landscape: approving biosimilar products in Mexico

Mexico03-11-2014José Trigueros

Who has legal interest in the grant of sanitary registrations for follow-on biologics? José Trigueros examines a recent case in Mexico that could have far-reaching ramifications.

Insurance 
companies v AstraZeneca

UK, US03-11-2014Jason Rutt

Jason Rutt considers the impact AstraZeneca’s recent US pay-for-delay case will have on the industry.

A bright future for AstraZeneca?

Sweden, UK, US03-11-2014

AstraZeneca has had a tough few years, with a clutch of patent expiries one of the most serious of its problems. So where does it go from here? To find out, LSIPR spoke to the Anglo-Swedish pharmaceutical company’s vice president of business development about the role IP is playing in its plans for future success.

TapImmune: tapping into innovative cancer treatments

US29-10-2014

In the competitive world of cancer treatment it’s becoming ever more important to stand out from the crowd. LSIPR speaks to TapImmune’s chief executive Glynn Wilson on why he thinks the company does.

An alliance for science

US30-09-2014

The Bay Area of California has one 
of the greatest concentrations of life 
sciences companies in the world, 
but its biotech community is being 
threatened by the seemingly 
unstoppable rise of large technology businesses. LSIPR spoke to Christopher Stewart, chair, and Robert Eyler, 
vice chair, of the new North Bay 
Life Science Alliance to find out 
how it plans to strengthen the network in the area.

LSIPR roundtable

UK, US30-09-2014

Earlier this month, the first LSIPR roundtable discussion took place in a London hotel, chaired by managing editor Martin Essex, with six invited experts and deputy editor 
Ed Conlon taking part. We’ll be publishing a special report on the event but, to whet your appetite, here’s how the discussion began—with a lively debate on the USPTO’s guidelines on patent-eligible subject matter in the wake of the Myriad and Mayo court decisions.

A hostile response to the USPTO’s guidelines

US04-09-2014

Sifting through the published comments on the USPTO’s Myriad/Mayo guidelines, LSIPR found them to be overwhelmingly negative.

Showing 271 to 280 of 334 results

LSIPR